rdf:type |
|
lifeskim:mentions |
umls-concept:C0005940,
umls-concept:C0042866,
umls-concept:C0087111,
umls-concept:C0181090,
umls-concept:C0302614,
umls-concept:C0332197,
umls-concept:C0439234,
umls-concept:C0456603,
umls-concept:C0486805,
umls-concept:C1419072,
umls-concept:C1706050,
umls-concept:C2316810
|
pubmed:issue |
3
|
pubmed:dateCreated |
2009-3-13
|
pubmed:abstractText |
Secondary hyperparathyroidism is a frequent complication of chronic kidney disease (CKD). The goal of treatment is to achieve circulating levels of parathyroid hormone (PTH) associated without oversuppression of bone turnover. This is commonly achieved by treatment with vitamin D analogs. Doses of vitamin D compounds are usually monitored by measurement of circulating levels of PTH.
|
pubmed:language |
eng
|
pubmed:journal |
|
pubmed:citationSubset |
IM
|
pubmed:chemical |
|
pubmed:status |
MEDLINE
|
pubmed:month |
Mar
|
pubmed:issn |
0301-0430
|
pubmed:author |
|
pubmed:issnType |
Print
|
pubmed:volume |
71
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
267-75
|
pubmed:meshHeading |
pubmed-meshheading:19281737-African Americans,
pubmed-meshheading:19281737-Biopsy,
pubmed-meshheading:19281737-Bone and Bones,
pubmed-meshheading:19281737-Cross-Sectional Studies,
pubmed-meshheading:19281737-Disease Progression,
pubmed-meshheading:19281737-Female,
pubmed-meshheading:19281737-Humans,
pubmed-meshheading:19281737-Hyperparathyroidism, Secondary,
pubmed-meshheading:19281737-Kidney Failure, Chronic,
pubmed-meshheading:19281737-Logistic Models,
pubmed-meshheading:19281737-Male,
pubmed-meshheading:19281737-Middle Aged,
pubmed-meshheading:19281737-Parathyroid Hormone,
pubmed-meshheading:19281737-Peptide Fragments,
pubmed-meshheading:19281737-Prospective Studies,
pubmed-meshheading:19281737-Renal Dialysis,
pubmed-meshheading:19281737-Renal Osteodystrophy,
pubmed-meshheading:19281737-Statistics, Nonparametric,
pubmed-meshheading:19281737-Treatment Outcome,
pubmed-meshheading:19281737-Vitamin D
|
pubmed:year |
2009
|
pubmed:articleTitle |
Absence of adynamic bone disease in African-Americans with CKD stage 5 after 3 years of vitamin D therapy guided by iPTH and the PTH-(1-84)/N-terminally truncated PTH fragments ratio.
|
pubmed:affiliation |
Henry Ford Health System, Detroit, Michigan, Santee, CA, USA.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|